Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 1.13
CPHD's Cash to Debt is ranked lower than
60% of the 211 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.88 vs. CPHD: 1.13 )
Ranked among companies with meaningful Cash to Debt only.
CPHD' s Cash to Debt Range Over the Past 10 Years
Min: 0.99  Med: 12.72 Max: 11006.5
Current: 1.13
0.99
11006.5
Equity to Asset 0.45
CPHD's Equity to Asset is ranked lower than
71% of the 186 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.58 vs. CPHD: 0.45 )
Ranked among companies with meaningful Equity to Asset only.
CPHD' s Equity to Asset Range Over the Past 10 Years
Min: 0.45  Med: 0.72 Max: 0.92
Current: 0.45
0.45
0.92
F-Score: 5
Z-Score: 5.50
M-Score: -3.21
WACC vs ROIC
5.66%
-10.11%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -6.09
CPHD's Operating margin (%) is ranked lower than
54% of the 199 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.48 vs. CPHD: -6.09 )
Ranked among companies with meaningful Operating margin (%) only.
CPHD' s Operating margin (%) Range Over the Past 10 Years
Min: -34.65  Med: -6.85 Max: 1.37
Current: -6.09
-34.65
1.37
Net-margin (%) -8.78
CPHD's Net-margin (%) is ranked lower than
56% of the 199 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.51 vs. CPHD: -8.78 )
Ranked among companies with meaningful Net-margin (%) only.
CPHD' s Net-margin (%) Range Over the Past 10 Years
Min: -29.75  Med: -9.84 Max: 0.95
Current: -8.78
-29.75
0.95
ROE (%) -13.27
CPHD's ROE (%) is ranked lower than
53% of the 187 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -4.35 vs. CPHD: -13.27 )
Ranked among companies with meaningful ROE (%) only.
CPHD' s ROE (%) Range Over the Past 10 Years
Min: -27.63  Med: -14.54 Max: 1.44
Current: -13.27
-27.63
1.44
ROA (%) -6.00
CPHD's ROA (%) is ranked higher than
50% of the 212 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.30 vs. CPHD: -6.00 )
Ranked among companies with meaningful ROA (%) only.
CPHD' s ROA (%) Range Over the Past 10 Years
Min: -19.19  Med: -7.46 Max: 1.04
Current: -6
-19.19
1.04
ROC (Joel Greenblatt) (%) -14.23
CPHD's ROC (Joel Greenblatt) (%) is ranked lower than
52% of the 211 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -10.22 vs. CPHD: -14.23 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
CPHD' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -189.08  Med: -21.75 Max: 5.58
Current: -14.23
-189.08
5.58
Revenue Growth (3Y)(%) 14.20
CPHD's Revenue Growth (3Y)(%) is ranked higher than
80% of the 141 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.80 vs. CPHD: 14.20 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
CPHD' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -15.5  Med: 18 Max: 56.7
Current: 14.2
-15.5
56.7
EPS Growth (3Y)(%) 30.70
CPHD's EPS Growth (3Y)(%) is ranked higher than
88% of the 117 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.10 vs. CPHD: 30.70 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
CPHD' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -37.4  Med: -8.15 Max: 39.2
Current: 30.7
-37.4
39.2
» CPHD's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-10-13)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q3 2015

CPHD Guru Trades in Q3 2015

Steven Cohen 175,000 sh (New)
RS Investment Management 414,860 sh (+33.60%)
PRIMECAP Management 2,363,400 sh (+1.21%)
Ron Baron 856,093 sh (+1.09%)
Mario Gabelli 214,500 sh (unchged)
Jim Simons Sold Out
Columbia Wanger 5,095,274 sh (-8.73%)
» More
Q4 2015

CPHD Guru Trades in Q4 2015

Manning & Napier Advisors, Inc 441,670 sh (New)
Mario Gabelli 231,500 sh (+7.93%)
Columbia Wanger 5,360,677 sh (+5.21%)
PRIMECAP Management 2,407,400 sh (+1.86%)
Steven Cohen Sold Out
RS Investment Management Sold Out
Ron Baron 14,368 sh (-98.32%)
» More
Q1 2016

CPHD Guru Trades in Q1 2016

Steven Cohen 318,000 sh (New)
Jim Simons 214,350 sh (New)
Manning & Napier Advisors, Inc 459,750 sh (+4.09%)
Mario Gabelli 238,500 sh (+3.02%)
PRIMECAP Management 2,407,500 sh (unchged)
Ron Baron 12,000 sh (-16.48%)
Columbia Wanger 3,789,947 sh (-29.30%)
» More
Q2 2016

CPHD Guru Trades in Q2 2016

Paul Tudor Jones 12,568 sh (New)
Manning & Napier Advisors, Inc 553,840 sh (+20.47%)
PRIMECAP Management 2,422,300 sh (+0.61%)
Mario Gabelli 238,500 sh (unchged)
Jim Simons 198,000 sh (-7.63%)
Ron Baron 8,500 sh (-29.17%)
Columbia Wanger 2,611,041 sh (-31.11%)
Steven Cohen 142,500 sh (-55.19%)
» More
» Details

Insider Trades

Latest Guru Trades with CPHD

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:NYSE:CRL, NYSE:ALR, NAS:VWR, NAS:PRXL, NAS:BRKR, NAS:ICLR, NAS:PRAH, OTCPK:CZMWY, NYSE:BIO.B, NAS:INCR, NAS:NEOG, NAS:EXAS, OTCPK:BMXMF, NYSE:PKI, NAS:MYGN, NAS:QGEN, NAS:AXDX, NAS:KANG, NAS:ABAX, NAS:ALOG » details
Traded in other countries:XEP.Germany,
Cepheid is a molecular diagnostics company that develops, manufactures and markets integrated systems for testing in the clinical market, as well as for application in its non-clinical market.

Cepheid was incorporated in the State of California on March 4, 1996. The Company is a molecular diagnostics company that develops, manufactures and markets integrated systems for testing in the clinical market, as well as for application in its non-clinical markets. The Company's systems enable molecular testing for organisms and genetic-based diseases by automating otherwise complex manual laboratory procedures. The Company's product portfolio consists of tests, reagents and systems for the clinical and non-clinical markets. The Company's two systems are the GeneXpert and SmartCycler. The GeneXpert system, offers services in the clinical market, integrates sample preparation in addition to DNA amplification and detection. The GeneXpert system is designed for user types ranging from reference laboratories and hospital central laboratories to satellite testing locations, such as emergency departments and intensive care units within hospitals and doctors' offices. The SmartCycler system integrates DNA amplification and detection to allow rapid analysis of a sample. Company faces competition from a number of companies that offer products to its target markets. Company has patents covering technologies of its own and has licensed technologies from others. In addition to patents, it rely on a combination of trade secrets, copyright and trademark laws, nondisclosure agreements, licenses and other contractual provisions and technical measures to maintain and develop its competitive position with respect to intellectual property. In the Clinical market, its products are regulated as medical device products by the FDA and comparable agencies in other countries. For the Non-Clinical market, all of its products are being produced under ISO 13485 and Quality System Regulations.

Guru Investment Theses on Cepheid

Baron Funds Comments on Cepheid - Feb 08, 2016

Shares of Cepheid (NASDAQ:CPHD), a provider of equipment for molecular diagnostic tests, were down in the fourth quarter. The company took down full year 2015 guidance by about 1% (excluding the effects of foreign currency), and took down longer-term operating margin guidance in 2016 and 2017. Given these moves, we sold the position. While we believe the company’s technology and reach of its products is unique, we are also mindful that it could take additional time to empirically assess the ultimate success of the expansion strategy. (Randy Gwirtzman)



From the Baron Funds Opportunity Fund fourth quarter 2015 commentary.



Check out Ron Baron latest stock trades

Top Ranked Articles about Cepheid

Baron Funds Comments on Cepheid Guru stock highlight
Shares of Cepheid (NASDAQ:CPHD), a provider of equipment for molecular diagnostic tests, were down in the fourth quarter. The company took down full year 2015 guidance by about 1% (excluding the effects of foreign currency), and took down longer-term operating margin guidance in 2016 and 2017. Given these moves, we sold the position. While we believe the company’s technology and reach of its products is unique, we are also mindful that it could take additional time to empirically assess the ultimate success of the expansion strategy. (Randy Gwirtzman) Read more...

Ratios

vs
industry
vs
history
Forward P/E 111.11
CPHD's Forward P/E is ranked lower than
95% of the 42 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 21.74 vs. CPHD: 111.11 )
Ranked among companies with meaningful Forward P/E only.
N/A
P/B 10.26
CPHD's P/B is ranked lower than
89% of the 179 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.47 vs. CPHD: 10.26 )
Ranked among companies with meaningful P/B only.
CPHD' s P/B Range Over the Past 10 Years
Min: 2.24  Med: 8.58 Max: 14.03
Current: 10.26
2.24
14.03
P/S 6.75
CPHD's P/S is ranked lower than
72% of the 181 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.27 vs. CPHD: 6.75 )
Ranked among companies with meaningful P/S only.
CPHD' s P/S Range Over the Past 10 Years
Min: 1.76  Med: 6.65 Max: 13.36
Current: 6.75
1.76
13.36
POCF 80.10
CPHD's POCF is ranked lower than
93% of the 80 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 18.96 vs. CPHD: 80.10 )
Ranked among companies with meaningful POCF only.
CPHD' s POCF Range Over the Past 10 Years
Min: 42.32  Med: 132.9 Max: 1895
Current: 80.1
42.32
1895
EV-to-EBITDA 2215.65
CPHD's EV-to-EBITDA is ranked lower than
100% of the 105 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 16.73 vs. CPHD: 2215.65 )
Ranked among companies with meaningful EV-to-EBITDA only.
CPHD' s EV-to-EBITDA Range Over the Past 10 Years
Min: -16576.6  Med: -36.75 Max: 13527.9
Current: 2215.65
-16576.6
13527.9
Current Ratio 3.79
CPHD's Current Ratio is ranked higher than
69% of the 206 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.43 vs. CPHD: 3.79 )
Ranked among companies with meaningful Current Ratio only.
CPHD' s Current Ratio Range Over the Past 10 Years
Min: 1.49  Med: 3.15 Max: 15.23
Current: 3.79
1.49
15.23
Quick Ratio 2.74
CPHD's Quick Ratio is ranked higher than
61% of the 206 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.14 vs. CPHD: 2.74 )
Ranked among companies with meaningful Quick Ratio only.
CPHD' s Quick Ratio Range Over the Past 10 Years
Min: 0.89  Med: 2.44 Max: 14.9
Current: 2.74
0.89
14.9
Days Inventory 190.18
CPHD's Days Inventory is ranked lower than
82% of the 165 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 88.85 vs. CPHD: 190.18 )
Ranked among companies with meaningful Days Inventory only.
CPHD' s Days Inventory Range Over the Past 10 Years
Min: 68.17  Med: 142.47 Max: 190.25
Current: 190.18
68.17
190.25
Days Sales Outstanding 40.64
CPHD's Days Sales Outstanding is ranked higher than
77% of the 160 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 64.52 vs. CPHD: 40.64 )
Ranked among companies with meaningful Days Sales Outstanding only.
CPHD' s Days Sales Outstanding Range Over the Past 10 Years
Min: 40.64  Med: 48.31 Max: 63.71
Current: 40.64
40.64
63.71
Days Payable 82.31
CPHD's Days Payable is ranked higher than
60% of the 149 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 60.15 vs. CPHD: 82.31 )
Ranked among companies with meaningful Days Payable only.
CPHD' s Days Payable Range Over the Past 10 Years
Min: 39.64  Med: 79.18 Max: 95.58
Current: 82.31
39.64
95.58

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -2.80
CPHD's 3-Year Average Share Buyback Ratio is ranked higher than
59% of the 129 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -5.80 vs. CPHD: -2.80 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
CPHD' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -95.2  Med: -7.05 Max: -2.2
Current: -2.8
-95.2
-2.2

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 37.40
CPHD's Price/Net Current Asset Value is ranked lower than
90% of the 117 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.50 vs. CPHD: 37.40 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
CPHD' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 2.35  Med: 17.14 Max: 50.57
Current: 37.4
2.35
50.57
Price/Tangible Book 12.21
CPHD's Price/Tangible Book is ranked lower than
78% of the 154 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.65 vs. CPHD: 12.21 )
Ranked among companies with meaningful Price/Tangible Book only.
CPHD' s Price/Tangible Book Range Over the Past 10 Years
Min: 2.11  Med: 10.55 Max: 20.59
Current: 12.21
2.11
20.59
Price/Projected FCF 32.35
CPHD's Price/Projected FCF is ranked lower than
96% of the 69 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.04 vs. CPHD: 32.35 )
Ranked among companies with meaningful Price/Projected FCF only.
CPHD' s Price/Projected FCF Range Over the Past 10 Years
Min: 17.83  Med: 32.99 Max: 3464
Current: 32.35
17.83
3464
Price/Median PS Value 1.02
CPHD's Price/Median PS Value is ranked higher than
54% of the 164 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.05 vs. CPHD: 1.02 )
Ranked among companies with meaningful Price/Median PS Value only.
CPHD' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.36  Med: 1.13 Max: 4.16
Current: 1.02
0.36
4.16
Earnings Yield (Greenblatt) (%) -0.90
CPHD's Earnings Yield (Greenblatt) (%) is ranked higher than
52% of the 205 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.00 vs. CPHD: -0.90 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
CPHD' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -0.9  Med: 0.2 Max: 0.3
Current: -0.9
-0.9
0.3

More Statistics

Revenue (TTM) (Mil) $564.2
EPS (TTM) $ -0.68
Beta0.54
Short Percentage of Float5.65%
52-Week Range $25.09 - 53.91
Shares Outstanding (Mil)73.01

Analyst Estimate

Dec16 Dec17
Revenue (Mil $) 622 707
EPS ($) -0.20 0.48
EPS w/o NRI ($) -0.20 0.48
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for CPHD

Headlines

Articles On GuruFocus.com
Baron Funds Comments on Cepheid Feb 08 2016 
Columbia Wanger Ups Stake in Fiesta Restaurant Feb 01 2016 
Weekly CEO Sells Highlight: SeaCube, Hasbro, Cepheid, Honeywell Apr 28 2013 
Weekly CFO Sales Highlight: CLB, CPHD, ALXN, RDEA, BCR Jul 31 2011 
CEPHEID (CPHD) SVP, CFO Andrew Miller sells 2,500 Shares Feb 28 2011 
CEPHEID Reports Operating Results (10-K) Feb 24 2011 
CEPHEID (CPHD) SVP, CFO Andrew Miller sells 2,500 Shares Feb 15 2011 
CEPHEID (CPHD) SVP, CFO Andrew Miller sells 2,500 Shares Feb 08 2011 
CEPHEID (CPHD) SVP, CFO Andrew Miller sells 10,000 Shares Dec 09 2010 
CEPHEID Reports Operating Results (10-Q) Nov 04 2010 

More From Other Websites
Proxy Statement Shows Danaher Faced Competition In Bid To Buy Cepheid Sep 26 2016
5 Notable NASDAQ Names Notched 52-Week Highs on Monday Sep 20 2016
Cepheid Announces Expansion of Molecular C. Difficile Product Sep 16 2016
Cepheid Announces Expansion Of The Most Comprehensive Molecular C. Difficile Product Portfolio On... Sep 15 2016
Cepheid Announces Expansion Of The Most Comprehensive Molecular C. Difficile Product Portfolio On... Sep 15 2016
Cepheid's (CPHD) Shares March Higher, Can It Continue? Sep 14 2016
Lifshitz & Miller Law Firm Announces Investigation of AECOM, American Farmland Company, Centene... Sep 13 2016
INVESTOR ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of Cepheid And... Sep 12 2016
Cepheid (CPHD) Stock Downgraded to 'Neutral' at Baird Sep 12 2016
Cepheid downgraded by Robert W. Baird Sep 12 2016
CEPHEID SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Announces the Investigation of Cepheid (CPHD) Over... Sep 09 2016
Cepheid Acquisition May Not Be in the Best Interests of CPHD Shareholders Sep 09 2016
SHAREHOLDER UPDATE: Brodsky & Smith, LLC Announces an Investigation of The Board of Directors of... Sep 08 2016
Cepheid Targets Development of a Point of Care HIV Viral Load Test From a Few Drops of Blood Sep 08 2016
Cepheid Targets Development of a Point of Care HIV Viral Load Test From a Few Drops of Blood Sep 08 2016
Cepheid – Value Analysis (NASDAQ:CPHD) : September 8, 2016 Sep 08 2016
Will Cepheid's (CPHD) Buyout by Danaher be a Strategic Fit? Sep 08 2016
How Cepheid Fits Strategically into DHR’s Portfolio Sep 07 2016
Harwood Feffer LLP Announces Investigation of Cepheid Sep 07 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)